Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 589 across all filing types
Latest filing 2016-01-11 Regulatory Filings
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions that the filing includes a press release announcing top line results from a Phase 2A clinical trial. The document is short (2962 characters) and primarily serves to furnish the press release as an exhibit. There is no detailed financial data or comprehensive report content. The document states that the press release is furnished as an exhibit and is not incorporated by reference into other filings. This fits the pattern of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-01-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a press release about the FDA acceptance of an Investigational New Drug application and completion of enrollment in a clinical trial. The document is short (3008 characters) and primarily serves to announce this event and furnish the press release as an exhibit. There are no financial statements or detailed financial data presented. The document explicitly states that the press release is furnished as an exhibit and is not incorporated by reference into other filings. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2015-12-29 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically mentions a press release about meeting enrollment targets in a clinical trial, and the press release is furnished as an exhibit. The document is short (2890 characters) and primarily serves to announce this event rather than provide detailed financial data or a full report. It does not contain financial statements or detailed analysis, nor is it a certification or voting result. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-12-18 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it contains a press release about a year-end update on clinical trials, furnished as an exhibit. The document is short (2960 characters) and primarily serves to announce the press release rather than provide detailed financial data or a full report. It does not contain financial statements or detailed analysis, nor is it a certification or voting result. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2015-12-09 English
FORM 4 SUBMISSION
Director's Dealing
2015-12-08 English
FORM 4 SUBMISSION
Director's Dealing
2015-12-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.